-
Following profitable Q3, Cardinal prepares for what may be a challenging FY2013
DUBLIN, Ohio — The recent loss of business from a key specialty pharmacy customer and the continued deluge of generic introductions will represent significant challenges for Cardinal Health in fiscal year 2013 as it approaches the year-end of its fiscal 2012, company executives told analysts during a conference call Thursday morning.
-
Sandoz acquires Fougera for $1.5 billion
BASEL, Switzerland — Novartis' generics division has acquired Fougera Pharmaceuticals, the company said Wednesday.
Sandoz announced the acquisition of Melville, N.Y.-based Fougera for $1.525 billion in cash. Fougera specializes in generic dermatology drugs, and Sandoz said the acquisition would make it the world's largest company in the space.